Peptide fact checks.

Nausea is the dominant effect in the trial record, severe in 12.9 per cent of subjects at the higher dose in the 2000 study. But the published case literature also contains rhabdomyolysis and renal impairment requiring intensive care, renal infarction affecting roughly half a kidney, and acute ischaemic priapism that failed drug and irrigation treatment and required surgical decompression, a time-critical emergency carrying permanent erectile-dysfunction risk. These are case reports: they prove occurrence, not frequency. The honest statement is that the frequency of serious harm is unknown because no surveillance system exists, not that serious harm is rare.

What this answer is based on

Observations or reports from people
This answer uses observations or reports from people. They can show what happened, but may not prove the substance caused it.

Applies to

The completeness of the adverse-effect picture. Case reports establish that these events happened after use with temporal association; they cannot establish incidence or causation.

FDA identifies Semax as a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. This identifies the free-base peptide and does not make other chemical forms or products interchangeable.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

Semax free base as identified in FDA's substance and briefing records; the acetate form is a separate chemical form.

FDA found no supporting literature for ADHD. A 24-person study measured resting brain-scan connections, not focus, memory, attention, or daily function.

What this answer is based on

No reliable studies showing this health result in people
No reliable study in people shows the health outcome in this statement.

Applies to

Focus, memory, and ADHD claims made for Semax; not a finding about the laboratory or animal literature.

FDA staff found insufficient evidence of effectiveness for cerebral ischemia, migraine, or trigeminal neuralgia. The two stroke studies listed here have important design and comparison limits.

What this answer is based on

No reliable studies showing this health result in people
No reliable study in people shows the health outcome in this statement.

Applies to

The uses reviewed by FDA in 2026; this does not assess every possible research question.

FDA says Semax free base and Semax acetate are not components of an FDA-approved drug. A drug registered in Russia does not create U.S. approval.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

United States approval status as reviewed August 30, 2026.

RAPS reported an 8-5 advisory-committee vote in favor of adding Semax to the 503A list. FDA says advisory recommendations are non-binding, and the briefing says FDA had not made its final determination. No final FDA rule or listing was identified in this review.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

The July 2026 advisory vote and U.S. 503A status as reviewed August 30, 2026; a recommendation is not a final FDA decision or drug approval.

FDA identifies Semax free base and Semax acetate as distinct active ingredients. PubChem identifies N-acetyl Semax amidate as a chemically modified substance. A shared name does not establish the same structure, quality, safety, or evidence.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

Chemical-form and product-identity comparisons; this is not a use or administration recommendation.

Yes. FDA lists Selank, Selanc, and TP-7 as names for one peptide with the sequence TKPRPGP. This record names the substance. It does not show that a related chemical form or sold product is the same.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

The Selank peptide in FDA's chemical record. Selank diacetate has a separate related record.

Yes. One randomized report compared Selank with medazepam in 62 people. Another randomized report included 70 people. Forty received Selank with phenazepam, and 30 received phenazepam alone. These small studies do not prove a broad benefit.

What this answer is based on

Health results from a study with randomly assigned groups
This answer uses a study that assigned people to groups by chance and measured a health outcome.

Applies to

Small studies in people with specific anxiety-related conditions. The reports do not establish a result for every anxiety condition or population.

The studies were small and compared Selank with another medicine. The reports did not clearly say whether people and researchers knew the assigned treatment. No large, repeated result against a placebo was found.

What this answer is based on

No reliable studies showing this health result in people
No reliable study in people shows the health outcome in this statement.

Applies to

A reliable treatment conclusion for anxiety disorders across people, settings, and products.

A 52-person study measured links between brain areas. It did not test focus, memory, or daily function. An earlier report mentioned a possible effect on thinking, but its study summary gave no clear result for these outcomes.

What this answer is based on

No reliable studies showing this health result in people
No reliable study in people shows the health outcome in this statement.

Applies to

Focus, memory, and daily-function outcomes in people who received a verified Selank study product.

No FDA-approved U.S. Selank product was found in the records checked. FDA's chemical record names the substance. It does not approve a drug. The request to add Selank acetate to a compounding list was withdrawn. That request was not approval.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

United States drug-approval and compounding records checked on August 30, 2026.

FDA has separate records for the main peptide and Selank diacetate, a related chemical form. A product name does not prove what it contains, its quality, or whether it matches the product used in a study.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

The peptide, its related chemical form, and each finished or compounded product must be checked separately.

The human studies were small and cannot show uncommon or long-term harms. FDA says important human safety information is missing for Selank acetate. For some ways of using it, FDA also warns of possible immune reactions from peptide clumps or related impurities.

What this answer is based on

No reliable studies showing this health result in people
No reliable study in people shows the health outcome in this statement.

Applies to

Long-term safety, uncommon harms, and the safety of each way it is used, chemical form, and finished product.

Yes. FDA's substance and briefing records use emideltide for DSIP and identify a nine-amino-acid sequence. This name match does not make free base, acetate, or online products equivalent.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

FDA substance identity records for DSIP and emideltide; this does not establish the identity or quality of an online product.

Small older human studies had mixed results. Some used controls, while others had important design limits. Together, they do not prove that DSIP improves sleep or treats insomnia.

What this answer is based on

No reliable studies showing this health result in people
No reliable study in people shows the health outcome in this statement.

Applies to

Small human sleep studies using different designs, products, routes, and follow-up periods; the results do not establish a general treatment benefit.

Small older studies examined withdrawal symptoms, but they did not establish that DSIP treats opioid or alcohol withdrawal. The findings do not support a general treatment claim.

What this answer is based on

No reliable studies showing this health result in people
No reliable study in people shows the health outcome in this statement.

Applies to

The small human withdrawal studies reviewed; this does not establish a treatment benefit for withdrawal or any other condition.

FDA's briefing did not identify an FDA-approved U.S. drug containing emideltide. The current U.S. 503A list also does not list DSIP or emideltide. A substance record or a foreign or online product is not U.S. drug approval.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

United States approval and 503A status as reviewed August 30, 2026.

The July 2026 committee vote was advisory. It did not itself change the 503A list or approve a drug. The current U.S. list does not show DSIP or emideltide, and no final FDA approval was identified in this review.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

The July 2026 advisory vote and United States 503A status as reviewed August 30, 2026; an advisory recommendation is not a final FDA decision or drug approval.

FDA separates emideltide free base and emideltide acetate. An online product may have a different form, contents, or quality. The names alone do not show that these products are interchangeable.

What this answer is based on

Official record or product label
This answer uses an official regulator record or a specific product label.

Applies to

Chemical-form and product-identity comparisons; this is not a use or administration recommendation.